Pharming Group N.V. (PHAR)
NASDAQ: PHAR · Real-Time Price · USD
11.21
-0.95 (-7.84%)
Jun 5, 2025, 4:00 PM - Market closed

Pharming Group Statistics

Total Valuation

Pharming Group has a market cap or net worth of $791.77 million. The enterprise value is $805.72 million.

Market Cap 791.77M
Enterprise Value 805.72M

Important Dates

The next estimated earnings date is Thursday, July 31, 2025, before market open.

Earnings Date Jul 31, 2025
Ex-Dividend Date n/a

Share Statistics

Pharming Group has 669.05 million shares outstanding. The number of shares has increased by 2.22% in one year.

Current Share Class n/a
Shares Outstanding 669.05M
Shares Change (YoY) +2.22%
Shares Change (QoQ) -9.59%
Owned by Insiders (%) n/a
Owned by Institutions (%) n/a
Float 669.68M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 2.47
Forward PS 3.02
PB Ratio 3.68
P/TBV Ratio 10.54
P/FCF Ratio 155.49
P/OCF Ratio 130.14
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 47.53, with an EV/FCF ratio of 158.23.

EV / Earnings n/a
EV / Sales 2.51
EV / EBITDA 47.53
EV / EBIT 59.80
EV / FCF 158.23

Financial Position

The company has a current ratio of 2.76, with a Debt / Equity ratio of 0.55.

Current Ratio 2.76
Quick Ratio 2.00
Debt / Equity 0.55
Debt / EBITDA 5.86
Debt / FCF 23.40
Interest Coverage 1.10

Financial Efficiency

Return on equity (ROE) is -6.78% and return on invested capital (ROIC) is 2.38%.

Return on Equity (ROE) -6.78%
Return on Assets (ROA) 1.99%
Return on Invested Capital (ROIC) 2.38%
Return on Capital Employed (ROCE) 4.14%
Revenue Per Employee $793,832
Profits Per Employee -$34,931
Employee Count 404
Asset Turnover 0.76
Inventory Turnover 0.61

Taxes

In the past 12 months, Pharming Group has paid $10.63 million in taxes.

Income Tax 10.63M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +22.57% in the last 52 weeks. The beta is 0.54, so Pharming Group's price volatility has been lower than the market average.

Beta (5Y) 0.54
52-Week Price Change +22.57%
50-Day Moving Average 9.15
200-Day Moving Average 8.69
Relative Strength Index (RSI) 55.86
Average Volume (20 Days) 3,291

Short Selling Information

Short Interest 1,301
Short Previous Month 1,622
Short % of Shares Out 0.00%
Short % of Float 0.00%
Short Ratio (days to cover) 0.39

Income Statement

In the last 12 months, Pharming Group had revenue of $320.71 million and -$14.11 million in losses. Loss per share was -$0.02.

Revenue 320.71M
Gross Profit 285.37M
Operating Income 13.47M
Pretax Income -15.41M
Net Income -14.11M
EBITDA 16.95M
EBIT 13.47M
Loss Per Share -$0.02
Full Income Statement

Balance Sheet

The company has $107.27 million in cash and $119.14 million in debt, giving a net cash position of -$11.87 million or -$0.02 per share.

Cash & Cash Equivalents 107.27M
Total Debt 119.14M
Net Cash -11.87M
Net Cash Per Share -$0.02
Equity (Book Value) 215.29M
Book Value Per Share 0.32
Working Capital 136.57M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $6.08 million and capital expenditures -$992,000, giving a free cash flow of $5.09 million.

Operating Cash Flow 6.08M
Capital Expenditures -992,000
Free Cash Flow 5.09M
FCF Per Share $0.01
Full Cash Flow Statement

Margins

Gross margin is 88.98%, with operating and profit margins of 4.20% and -4.40%.

Gross Margin 88.98%
Operating Margin 4.20%
Pretax Margin -1.14%
Profit Margin -4.40%
EBITDA Margin 5.29%
EBIT Margin 4.20%
FCF Margin 1.59%

Dividends & Yields

Pharming Group does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -2.22%
Shareholder Yield -2.22%
Earnings Yield -1.78%
FCF Yield 0.64%

Analyst Forecast

The average price target for Pharming Group is $30.00, which is 167.62% higher than the current price. The consensus rating is "Strong Buy".

Price Target $30.00
Price Target Difference 167.62%
Analyst Consensus Strong Buy
Analyst Count 3
Revenue Growth Forecast (5Y) 9.79%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Pharming Group has an Altman Z-Score of 2.19 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 2.19
Piotroski F-Score 6